XML 55 R44.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Reporting [Abstract]                
Number of reportable segments | segment             1  
Number of operating segments | segment             1  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Total revenues $ 72,839     $ 110,708     $ 108,273 $ 130,609
Cost of product sales 0     168     0 614
Cost of manufacturing services 11,589     1,702     25,894 6,195
Research and development 32,709     40,543     113,198 138,304
Selling, general and administrative 9,905     14,104     29,925 43,237
Net loss 16,822 $ (36,251) $ (41,036) 56,309 $ (55,664) $ (52,190) (60,465) (51,545)
Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Total revenues 72,839     110,708     108,273 130,609
Cost of product sales 0     168     0 614
Cost of manufacturing services 11,589     1,702     25,894 6,195
Research and development 32,709     40,543     113,198 138,304
Selling, general and administrative 9,905     14,104     29,925 43,237
Other segment income (loss), net (1,814)     2,118     279 6,196
Net loss 16,822     56,309     (60,465) (51,545)
Lorigerlimab | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 7,763     6,268     27,188 26,897
MGC030 | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 7,045     4,000     15,217 8,900
MGC028 | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 3,443     4,280     12,118 20,158
Vobramitanmab duocarmazine | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 3,316     10,514     15,969 32,221
Next-generation T-cell engagers | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 3,104     1,994     8,894 6,575
MGC026 | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 3,028     3,010     11,942 10,865
MGD024 | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 2,125     2,341     7,032 7,285
ADC | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 862     1,541     4,718 5,918
Margetuximab | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development 0     2,089     650 8,077
Other programs | Main Segment                
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]                
Research and development $ 2,023     $ 4,506     $ 9,470 $ 11,408